Year Founded
2002
Ownership
Private
Employees
~6
Stage
Phase 1
Modalities
Small molecule

Helperby Therapeutics General Information

Lead product HY001 has completed Phase 1 studies showing synergistic activity of antibiotic combinations, with colistin being used at 1/3rd of recommended dose while maintaining efficacy against resistant strains

Contact Information

Website
Primary Industry
Biotech
Corporate Office
London,
United Kingdom

Drug Pipeline

HY001
Phase 1
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Helperby Therapeutics's pipeline data

Book a demo

Key Partnerships

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Helperby Therapeutics Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Helperby Therapeutics's complete valuation and funding history, request access »